|
|
The exercise price for warrants of series TO 3 has been determined |
|
|
Notice to attend the extraordinary general meeting in Scibase Holding AB (publ) |
|
|
Interim report |
|
|
The Board of Directors in SciBase resolves on an offer to repurchase outstanding warrants of series TO 2 and intends to resolve on a rights issue of shares of approximately SEK 83 million |
|
|
SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million |
|
|
Nomination Committee appointed for SciBase Holding's Annual General Meeting in 2026 |
|
|
Nevisense Used in Fundamental Skin Barrier Research on Atopic Dermatitis |
|
|
SciBase receives initial order for clinical study from Castle Biosciences |
|
|
Main owners strengthen their position in SciBase |
|
|
New Clinical Publication in Karger Dermatology Confirms Reader Studies as Key to Validating Nevisense |
